

# Mechanistic Insights: *Drynaria quercifolia* Rhizome Chloroform Fraction on S-Phase Cell Cycle Progression in Breast Cancer

**Mudavath Ravi Naik<sup>1</sup>, M Manjunath Setty<sup>2</sup>, Praveen Thaggikuppe Krishnamurthy<sup>1\*</sup>**

<sup>1</sup>Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India.

<sup>2</sup>Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka-576104, India.

## Abstract

Breast cancer is the most common gynaecological cancer in women, affecting more than 2.3 million women world-wide. Plant derived agents have been the most important source for identifying the leads in the development of anticancer drugs. The plant *Drynaria quercifolia* (DQ) is reported to be biologically active against various life affecting diseases including cancer. However, no extensive scientific investigations have been conducted to establish the anticancer activity of DQ. In this regard, the current study was carried out to investigate the anticancer properties of DQ Rhizome (DQR) fractions using bioassay guided fractionation. Successive soxhlet extraction of DQR was carried out with n-hexane, chloroform, ethylacetate and methanol, to get respective fractions. The *in vitro* anticancer activity of prepared fractions were assessed in Triple-negative breast cancer (TNBC) cells (MDA-MB-231). The cell viability, cell cycle and apoptosis were assessed using MTT assay, PI flowcytometry, and Annexin V-FITC/PI & AO/EtBr dual stain analysis respectively. Among the fractions, chloroform fraction showed a significant anticancer activity (CTC<sub>50</sub> 31.70±0.84µg/ml) by interfering with the S-phase of the cell cycle. Further, chloroform fraction promotes early and late-stage apoptosis in TNBC MDA-MB-231 cells. The current investigation provides information on the anticancer activity of the DQR chloroform fraction.

**Keywords:** Apoptosis, Breast cancer, Cell cycle, *Drynaria quercifolia*, Rhizome

**Full-length article** \*Corresponding Author, e-mail: [praveentk7812@gmail.com](mailto:praveentk7812@gmail.com), [praveentk@jssuni.edu.in](mailto:praveentk@jssuni.edu.in)

## 1. Introduction

Triple-negative Breast cancer (TNBC) is one of the utmost aggressive and lethal cancer in women affecting more than 2.3 million people worldwide [1–3]. TNBC possess high rates of tumor relapse and metastatic features. Absence of molecular targets such as, HER2 (Human epidermal growth factor 2), ER (estrogen receptors) and PR (progesterone receptors) make the TNBC treatment difficult [4,5]. The primary risk factors includes age, genetic, hormonal changes, life style, reproductive and environmental factors [6,7]. Natural materials and their derivatives have a long history of usage in the treatment of numerous illnesses, including cancer [8,9]. Approximately 80% of global residents rely on plant-based medicines for their health care and currently more than 60% of natural derived agents are helpful in the treatment of cancer [10,11]. *Drynaria quercifolia* (DQ) is an epiphytic fern with a reduced root system attached to the host plant [12]. The plant profile is given in Table 1 [13–16] and there are

different phytoconstituents with diverse pharmacological activity were reported for DQ Rhizome (DQR) [17–24], reported phytoconstituents were given in Table 2. However, no extensive scientific investigations have been conducted to establish the anticancer activity of DQ. In this regard, the current study was carried out to investigate the anticancer properties of DQR fractions using bioassay guided fractionation.

## 2. Materials and Methods

### 2.1. Cell line, culture condition and reagents

The National Centre for Cell Sciences (NCCS) in Pune, India, provided MDA-MB-231 triple-negative human breast cancer cells and HEK 293 human embryonic kidney cells. The cells were grown at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> in F12 and DMEM (Gibco, USA) supplemented with 10% (v/v) FBS, 100 U/ml penicillin, and 100 g/mL streptomycin. Cell culture grade chemicals included MTT (Sigma Aldrich, USA), RNase (HiMedia,

India), PI (Sigma Aldrich, USA), Annexin V FITC (BD Biosciences, USA) and AO/EtBr (Sigma Aldrich, India).

## 2.2. Collection and authentication of plant

DQR was collected from Manipal University, Mangalore, Karnataka, India, in January 2021. The plant material was authenticated by T. Rasingam, Scientist In-charge, Botanical Survey of India (BSI), Hyderabad, Telangana, India. A voucher specimen reference Ref.No. BSI/DRC/2021-22/Tech./Identification/163.

## 2.3. Fractionation of DQR

A total of 200 g of DQR dry powder was extracted using n-hexane, chloroform, ethylacetate and methanol (500 ml) in a series of Soxhlet extractions. The fractions obtained were filtered and evaporated at 40 degrees Celsius using a rotary evaporator under reduced pressure.

## 2.4. HPTLC fingerprinting analysis of DQR fractions

CAMAG high performance thin layer chromatography (HPTLC) analyzer (CAMAG, Muttenz, Switzerland) was used to commence the HPTLC fingerprinting analysis of DQR fractions. Using a CAMAG Linomat 5 applicator, ten microlitre (50 µg/ml) of each methanol-prepared fraction was spotted on a precoated silica gel TLC plate (60 F254, Merck, Darmstadt, Germany). TLC was developed in a CAMAG twin trough development chamber with the appropriate mobile phases (Table 3). After development, the TLC plates were dried and scanned at 254 nm and 366 nm with the CAMAG HPTLC Scanner III and WIN CATS software (version 4.3). Following scanning, the plates were derivatized with anisaldehyde sulfuric acid reagent and imaged at 520 nm once again.

## 2.5. In vitro cytotoxicity and anticancer activity of DQR fractions

The cytotoxicity study and *in vitro* anticancer potential of DQR fractions were carried out using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium (MTT) assay. The cytotoxicity study of DQR fractions (0-1000 µg/ml) were carried out against HEK 293 cell line. All the fractions showed a CTC50 > 500 µg/ml. Therefore, the DQR fractions with concentration range of 0-500 µg/ml were used for anticancer study against MDA-MB-231 cells. HEK 293 & MDA-MB-231 cells were seeded ( $1 \times 10^4$  cells/well) into 96-well culture plates and incubated at 37 °C for 24 hours with 5% CO<sub>2</sub> and 95% air. After a 24-hour incubation period, the cells were exposed to various doses of DQR fractions. 20 µl of MTT reagent (5 mg/ml) was added after 48 hours of treatment and incubated for 3 hours. The resultant formazan was dissolved in 100 µl of DMSO. Finally, the absorbance at 570 nm was measured with a microplate reader (Tecan-Spark, Tecan Austria GMBH, Austria).

The percent cell viability was calculated by using the following formula:

$$\text{Cell viability} = (\text{OD treatment}/\text{OD control}) \times 100$$

Based on the significant activity, further the anticancer property of chloroform fraction was studied by using flowcytometry cell cycle analysis and cell apoptosis by using Propidium iodide (PI) staining, Annexin V-FITC (Flouorescein isothiocyanate)/PI & Acridine

orange/ethidium bromide (AO/EtBr) dual stain on MDA-MB-231 cells.

## 2.6. Effect of chloroform fraction on cell cycle

PI stain and flow cytometry were used to examine the distribution of cell cycle phases. MDA-MB-231 cells were fixed at a density of  $1 \times 10^6$  in a 6 cm culture plate and incubated for 24 hours. After 24 hours, cells were exposed to different concentrations (10, 20 & 50 µg/ml) of chloroform fraction for 48 hours. After incubation, cells were collected, washed with phosphate-buffered saline (PBS), and fixed for 30 minutes on ice in 1ml of 70% ice-cold ethanol. The cells were rinsed with PBS before being exposed for 1 hour at 37 °C with 15 µl of RNase A (0.1 mg/ml). Cellular DNA was stained with PI (10 µl, 40 µg/ml) and incubated at room temperature for 30 minutes in the dark. CyFlow Space (Partec, USA) flowcytometry was used to determine the DNA content and the BD FACSD software was used to calculate the percentage of DNA dispersion in the G0/G1, S & G2/M phases.

## 2.7. Effect of chloroform fraction on apoptosis

The proapoptotic activity of chloroform fraction was assessed in TNBC cells using Annexin V-FITC/ PI & AO/EtBr double staining assay.

### 2.7.1. Annexin V-FITC & PI double staining assay

The Annexin V-FITC/PI double stain technique is used to detect apoptotic cells (early apoptotic (EA) & late apoptotic (LA) cells). The assay was performed in accordance with the manufacturer's instructions (BD Biosciences, USA). MDA-MB-231 cells ( $1 \times 10^6$ ) were cultivated in a 6 cm culture plate for 24 hours before being treated with 10, 20 & 50 µg/ml of chloroform fraction for 48 hours. After the treatment period, the cells were collected and washed with cold PBS. The cell pellets were resuspended in Annexin V-binding buffer before being stained in the dark for 15 minutes at room temperature with 5 µl of annexin V-FITC and 5 µl of PI. Within 1 hour, flow cytometry was used to examine apoptotic cells.

### 2.7.2. AO/EtBr dual staining assay

In a 6-well culture plate, MDA-MB-231 ( $1 \times 10^6$ ) cells were seeded and incubated for 24 hours. Following incubation, the cells were treated with the appropriate doses of chloroform fraction (10, 20 & 50 µg/ml) and incubated for 48 hours. Following the incubation period, cells were washed twice with PBS, and 25 µl of AO (100 mg/ml) and EtBr (100 mg/ml) combination was added to cells and incubated at room temperature for 5 minutes. A fluorescent microscope was used to detect the stained cells.

## 3. Result

### 3.1. Fractionation of DQR

The percentage yield of DQR fractions were given in Table 4. Among the fractions, methanol fraction shows highest yield (1.52%).

### 3.2. HPTLC fingerprinting analysis of DQR fractions

The HPTCL densitogram spectrums of DQR fractions scanned at 254 nm, 366 nm and 520 nm (before and after derivatization with anisaldehyde sulphuric acid reagent) were given in Fig 3B & Table 5.





























Figure 1. Graphical Abstract














Table 1. Plant profile – DQ





Kingdom	Plantae
Division	Pteridophyta
Class	Polypodiopsida/pteridopsida
Order	Polypodiales
Family	Polypodiaceae
Subfamily	Polypodiaceae
Genus	<i>Drynaria</i>
Species	<i>Quercifolia</i>
<b>Vernacular name</b>	
English	Oakleaf fern
Tamil	Mudavattukal
Sanskrit	Aswakatri
Malayalam	Matipanna, pannakizhangu, pannikizhangu
Kannada	Hanuma hastha, hanuma paada
Hindi	Asvakatri, Katikapan, basingh.
<b>Distribution</b>	India, Bangladesh, Malaysia, Southeast Asia, New Guinea, China, The Philippines, Pakistan, North America, Sri Lanka, Indonesia and Australia
<b>Traditional uses</b>	Typhoid, hectic fever, tuberculosis, asthma, jaundice, relieve head ache and throat infection, reduce cholera and urinary problems, reduce muscle pain, body pain, rheumatic pain and knee pain, and to restore hair growth

**Table 2.** List of Phytoconstituents isolated from DQ plant with their reported pharmacological activity

Sl.NO	Name of the phytochemical	Structure	Pharmacological activity reported	Reference
1	Pentanoic Acid, Methyl Ester (PAME)		-	-
2	Undecane (UDC)		Anti-allergic, anti-inflammatory	[25]
3	Cyclohexasiloxane, Dodecamethyl- (CHDM)		Antifungal, antibacterial	[26,27]
4	1, 2-Benzenedicarboxylic Acid, Diethyl Ester (BDDE)		Plasticizer, antimicrobial	[28,29]
5	Cyclooctasiloxane, Hexadecamethyl- (COSHDM)		-	-
6	1, 3-Diphenyl-1, 3, 5, 5-Tetramethyl-cyclotrisiloxane (DPTMCT)		-	-
7	Benzenesulfonamide, 3-Amino-4-Hydroxy- (BSAH)		-	-
8	Octadecamethylcyclononasiloxane (ODMCS)		Antifungal, pesticide	[30,31]
9	Benzenepropanoic Acid, Alpha., 4-Bis (Acetyloxy)-, Methyl Ester (BPABME)		-	-
10	1, 2-Benzenedicarboxylic Acid, Bis (2-Methylpropyl) Ester (BDCBMPE)		Anticancer	[32]
11	2-Pyridinepropanamide, N-Phenyl- (PPNP)		-	-

12	Silane, [1, 3, 5-Benzenetriyltris (Oxy)] Tris [Trimethyl- (SBTTTM)]		Antibacterial	[33]
13	Hexadecanoic Acid, Methyl Ester (HDME)		Antioxidant, anti-inflammatory, nematocide, insecticide, antiandrogenic, hemolytic, hypo – cholesterolemic, anticancer, antihistaminic, antieczemic, antiacne, antiarthritic, anticoronary	[34–36]
14	Palmitic Acid (PA)		Anti-inflammatory, antioxidant, hemolytic	[37]
15	1, 2-Benzenedicarboxylic Acid, Dibutyl Ester (BDCDE)		Antimicrobial, antifouling, antitumour agent	[38,39]
16	Nonamethyl, Phenyl-, Cyclopentasiloxane (NMPCPS)		-	-
17	1-Octadecanol (OD)		Antimicrobial	[28,38]
18	9, 12-Octadecadienoic Acid (Z, Z)-, Methyl Ester (ODDME)		Antibacterial, anticancer	[37,40]
19	9-Octadecenoic Acid (Z)-, Methyl Ester (ODZME)		Antioxidant, anticancer, anti-inflammatory, hypocholesterolemic, dermatogenic, anemiagenic	[34,36,38]
20	Tetracosamethylcyclododecasiloxane (TMCDS)		-	-
21	Octadecanoic Acid, Methyl Ester (ODME)		Antimicrobial	[34]
22	9-Octadecenoic Acid (OEOD)		Anticancer, anemiagenic, antiandrogenic, antitumour, dermatogenic	[41]
23	Pentamethyl Phenyl-Disilane (PMPDS)		-	-
24	(4-Chlorophenyl) Methanesulfonamide (CPMS)		-	-
25	1, 2-Benzenedicarboxylic Acid, Diisooctyl Ester (BDDIOE)		Antimicrobial	[42]

26	Phosphine Oxide, Triphenyl- (POTP)		-	-
27	3, 4-dihydroxy benzoic acid (DHBA)		Antibacterial, anti-viral, neuroprotective, anti-atherosclerotic, antifibrotic, anti-ageing, anti-ulcer, anticancer, anti-inflammatory, analgesic, antioxidant, cardioprotective, hepatoprotective, antihypertensive, bronchodilatory, antispasmodic	[43]
28	Naringin (NRGN)		Antidiabetic, cardioprotective, anti-inflammatory, antioxidant, neuroprotective, hepatoprotective, antitumour, antiviral, antibacterial, antiadipogenic, anticancer	[44–47]
29	2,4,6-cycloheptatrien-1-one,3,5-bistrimethylsilyl (CHBTMS)		Antioxidant	[48]
30	1,2-bis(trimethylsilyl) benzene (BTMB)		Antimicrobial, antioxidant	[49]
31	2-Propanoal, 1-chloro-3-isopropoxy- (PCIP)		-	-
32	Trimethyl-(4-trimethyl silylphenyl) silane (TTSPS)		-	-
33	3,5-Dichloro-4-(dodecylsulfanyl)-2,6-dimethylpyridine (DDSDP)		-	-
34	1-heptyn-4-ol (HPTN)		-	-
35	1-Chloro-3-propoxy-2-propanol (CPP)		-	-
36	2-myristynoyl-glycinamide (MGC)		Antimicrobial	[50]
37	tert-Butyl(2-isopropyl-5-methylphenoxy) dimethyl silane (TBDS)		-	-
38	3,4-dicarbomethoxybenzoic acid (DMBA)		-	-

39	Friedelin (FRDLN)		Antibacterial, antifungal, anti-inflammatory, analgesic, antipyretic, antihypertensive, antidiabetic, anticancer	[37,51–54]
40	Epifriedelinol (EFDRLN)		Anticancer	[55]
41	$\beta$ -amyrin (BAMRN)		Gout, hyperpigmentation, analgesic, anti-inflammatory, anticonvulsant, antidepressive, hepatoprotective, antihyperglycemic, hypolipidemic	[56–58]
42	$\beta$ -sitosterol (BSS)		Anticancer	[59,60]

**Table 3.** HPTLC mobile phase of DQR fractions

S. NO	Fractions	Mobile phase
1	n-hexane	Hexane: Ethylacetate (9:1)
2	Chloroform	Hexane: Ethylacetate (8:2)
3	Ethylacetate	Petroleum ether: Ethylacetate (8:2)
4	Methanol	Chloroform: Methanol (6:4)

**Table 4.** Percentage yield of fractions by soxhlation

S. No	Solvent	DQR (200g)	
		Yield (g)	Yield (%)
1	n-hexane	2.12	1.06
2	Chloroform	1.6	0.8
3	Ethylacetate	1.84	0.92
4	Methanol	3.04	1.52

**Table 5.** HPTLC fingerprint profile of DQR fractions

Track	Peak	Fractions											
		n-hexane			Chloroform			Ethylacetate			Methanol		
		Rf	Area	Area%	Rf	Area	Area%	Rf	Area	Area%	Rf	Area	Area%
254 nm	1	0.07	915	4.69	0.06	2685.6	8.29	0.06	563.8	1.70	0.05	3179.6	5.10
	2	0.12	406	2.08	0.24	915.9	2.83	0.08	179	0.54	0.22	13983.6	22.45
	3	0.15	676.1	3.46	0.30	796.6	2.46	0.13	209	0.63	0.36	646	1.04
	4	0.22	1589.3	8.14	0.40	7906	24.40	0.15	156.5	0.47	0.41	1383.3	2.22
	5	0.29	2856.6	14.63	0.49	446.8	1.38	0.18	460.6	1.39	0.57	6138.6	9.85
	6	0.52	13085.7	67.01	0.82	258.1	0.80	0.41	1456.7	4.40	0.69	15583.2	25.01
	7				0.88	626.8	1.93	0.49	1044.4	3.15	0.75	2277.1	3.66
	8				0.90	1624.7	5.01	0.59	3475.6	10.50	0.84	764.3	1.23
	9				0.94	17145.9	52.91	0.68	1584	4.78	0.92	18341.9	29.44
	10							0.80	326.5	0.99			
	11							0.93	15886	47.98			
	12							0.95	7769	23.46			
366 nm	1	0.06	279.8	0.45	0.1	2114.5	4.92	0.05	269.8	1.02	0.04	425.7	1.92
	2	0.08	470.9	0.75	0.19	11150.3	25.95	0.06	144.3	0.54	0.08	1288.3	5.82
	3	0.10	848	1.36	0.27	10215.8	23.78	0.09	839.6	3.16	0.23	2964.4	13.40
	4	0.17	39731	63.54	0.43	18468.3	42.99	0.19	1860.7	7.01	0.25	3435.3	15.52
	5	0.20	431	0.69	0.62	388.9	0.91	0.27	5198.2	19.59	0.37	1138.8	5.15
	6	0.25	14527.2	23.23	0.88	622.5	1.45	0.43	11800.5	44.48	0.45	1267.5	5.73
	7	0.34	1099.2	1.76				0.59	2124.6	8.01	0.50	443.3	2.00
	8	0.43	2165.5	3.46				0.75	1028.9	3.88	0.55	680.8	3.08
	9	0.47	1132.5	1.81				0.8	1523.4	5.74	0.62	5267.7	23.80
	10	0.64	232.2	0.37				0.85	1738.3	6.55	0.72	2404.4	10.87
	11	0.67	505	0.81							0.74	2813.4	12.71
	12	0.71	587.9	0.94									
	13	0.8	518	0.83									
520 nm	1	0.06	836.6	0.55	0.06	2441.4	1.77	0.09	613.3	0.94	0.07	4980	9.07
	2	0.1	6864.7	4.53	0.1	1178	0.85	0.18	6277	9.63	0.17	6333.9	11.54
	3	0.13	5044.2	3.33	0.17	6773.4	4.91	0.25	6463	9.91	0.25	6701.6	12.21
	4	0.18	306.7	0.20	0.2	2514.5	1.82	0.30	4962	7.61	0.41	390.7	0.71
	5	0.24	1225.3	0.81	0.25	14223.4	10.31	0.49	9860.1	15.12	0.49	985.1	1.79
	6	0.30	5013.2	3.30	0.30	6324.1	4.58	0.60	26110.8	40.05	0.57	1618.4	2.95
	7	0.36	25846.7	17.04	0.36	3175.4	2.30	0.93	8101.5	12.43	0.70	14980	27.29
	8	0.49	74380	49.03	0.38	3499	2.54	0.95	2810.5	4.31	0.76	9407.9	17.14
	9	0.72	32171.5	21.21	0.49	23017.4	16.68				0.87	207.5	0.38
	10				0.58	44998.6	32.62				0.91	666	1.21
	11				0.73	1057.1	0.77				0.94	8620.8	15.71
	12				0.78	3080	2.23						
	13				0.82	401	0.29						
	14				0.87	2027.1	1.47						
	15				0.89	2653.8	1.92						
	16				0.93	20596.8	14.93						




**Table 6.** CTC<sub>50</sub> values of DQR fractions

Fractions	CTC <sub>50</sub> (µg/ml)	
	Hek 293	MDA MB 231
n-hexane	523.05±3.46	54.77±0.99
Chloroform	518.85±4.87	31.70±0.84
Ethylacetate	552.00±4.52	69.55±1.30
Methanol	540.50±2.54	62.73±1.42




**Fig2.** Images of DQR and DQ leaf (DQL)




**Fig 3. (A)**


Chromatograms of DQR fractions, before derivatization: under day light, UV 254 nm and UV 366 nm; after derivatization: under day light and UV 366 nm (B) HPTLC Finger print of DQR fractions scanned at 254 nm, 366 nm and 520 nm (a) n-hexane fraction (b) Chloroform fraction (c) Ethylacetate fraction (d) Methanol fraction.



**Fig 4.** Effect of chloroform fraction on MDA-MB-231 cell cycle



**Fig 5.** The effect of chloroform fraction on MDA-MB-231 cell apoptosis



**Fig 6.** AO/EtBr double staining effect of chloroform fraction on MDA-MB-231 cells apoptosis. Green arrows represent live cells; yellow arrows represent EA cells and red arrows represent LA cells (A) Control (B) 10 µg/ml (C) 20 µg/ml (D) 50 µg/ml

Among the scanned fractions at 254 nm, the ethylacetate fraction shows highest peaks (12), followed by chloroform (9), methanol fractions (9) and n-hexane (6). Among the

scanned fractions at 366 nm, the n-hexane fraction shows highest peaks (13), followed by methanol fraction (11), ethylacetate fraction (10) and chloroform fraction (6).



Among the scanned fractions at 520 nm, the chloroform fraction shows highest peaks (16), followed by methanol fraction (11), n-hexane fraction (9) and ethylacetate fraction (8) respectively.

### 3.4. *In vitro* cytotoxicity and anticancer activity of DQR fractions

Table 6 represents the *in vitro* cytotoxicity and anticancer activity of DQR fractions on Hek 293 and MDA-MB-231 cells. All the fractions showed a  $CTC_{50} > 500$   $\mu\text{g/ml}$  against Hek 293 cells, among the fractions, chloroform fraction exhibited significant anticancer activity with an  $CTC_{50}$  value of  $31.70 \pm 0.84$   $\mu\text{g/ml}$  followed by n-hexane fraction ( $CTC_{50}$   $54.77 \pm 0.99$ ), methanol fraction ( $CTC_{50}$   $62.73 \pm 1.42$ ) and ethylacetate fraction ( $CTC_{50}$   $69.55 \pm 1.30$ ).

### 3.6. Effect of chloroform fraction on apoptosis

#### 3.6.1. Annexin V-FITC /PI double staining assay

Fig 4 illustrates the findings of the Annexin V-FITC/PI double staining test. In both apoptotic stages, the chloroform fraction at doses of 10, 20 & 50  $\mu\text{g/ml}$  demonstrated considerable proapoptotic activity when compared to untreated control cells. The percentage increase in EA and LA cells was determined to be 6.06% & 8.79% at 10  $\mu\text{g/ml}$ , 28.18% & 17.37% at 20  $\mu\text{g/ml}$ , 27.35% & 20.42% at 50  $\mu\text{g/ml}$  respectively.

#### 3.6.2. AO/EtBr double staining assay

The results of AO/EtBr dual staining were given in Fig 5. The chloroform fraction has shown a dose dependent proapoptotic activity in MDA-MB-231 cells by decrease of viable cells (green fluorescence) and increasing the proportion of cells undergoing EA & LA when compared with the untreated control cells. The proapoptotic activity was confirmed by characteristic features such as chromatin condensation and membrane blebbing (Fig 5). The nuclear structure of normal cells resulted in green fluorescence, whereas EA cells resulted with bright green fluorescence, by the interposition of AO with the fragmented DNA. The cell's undergoing LA was identified by binding of EtBr to denatured DNA which results reddish-orange color.

## 4. Discussion

Plant-based anticancer medicines have been a major source in the development of anticancer agents [10]. The current study was focused the anticancer mechanism of DQR fractions (n-hexane, chloroform, Ethylacetate, and methanol) on MDA MB 231 cells. Among the fractions, the chloroform fraction exhibited significant anticancer activity with a  $CTC_{50}$  value of  $31.70 \pm 0.84$   $\mu\text{g/ml}$  (Table 6). The chloroform fraction showed a significant arrest of MDA-MB-231 cells at S-phase in a dose dependent manner (Fig 3) and a significant increase of EA and LA cell population (Fig 4 & 5). Among the phytoconstituents of DQ, around 42 phytoconstituents (although not directly isolated and reported) found to show anticancer activity in various *in vitro* models (Table 2). These phytoconstituents includes BSS, FRDLN, BAMRN, NRGN, BDCBMPE, DHBA, EFDRLN, HDME, BDCDE, ODDME, ODZME and OEO [54,61–69].

The BSS is reported to exhibit significant cytotoxic activity in liver cancer cells (HepG2 & Huh7) via inducing apoptosis and by activating caspase-3 and caspase-9 [70]. According to the Zhao et al., the phytochemical BSS prevents cell proliferation & enhances apoptosis in SGC-7901 human stomach cancer cells through increased expression of pro-caspase-3 and Bax and by decreased expression of Bcl-2 [71]. BSS significantly induces the cell apoptosis and cell cycle arrest of G0/G1 phase in breast cancer MDA-MB-231 cells by decreasing the level of CDK4 & cyclin D1 and by increasing the level of p21/Cip1 and p27/Kip1 [72]. Chang et al., reported that FRDLN triterpenoid shows significant anticancer activity against human AML-196 leukemia cells by inducing apoptosis via upregulating the level of caspase-3, 8, 9 and by blockage of MEK/ERK and PI3K/AKT signalling pathways [73]. Subash-Babu et al., reported that FRDLN as a potential anticancer agent against human breast cancer by inducing apoptosis by regulating the increased level of Cdkn1a, pRb2, p53, Nrf2, caspase-3 expression and by decreased level of Bcl-2, mdm2 & PCNA expression [74]. According to Wen et al., the anticancer impact of BAMRN in liver carcinoma cells (Hep-G2) is mediated by induction of apoptosis, interruption of the cell cycle, and activation of the JNK and P38 signalling pathways [75].

Banjerpongchai et al., reported that, the flavonoid phytochemical NRGN induces apoptosis in HepG2 cells via mitochondria-mediated stimulation of caspase-9 and caspase-8-mediated proteolysis of Bid [76]. The phytochemical NRGN inhibits the bladder cancer cell proliferation and induces G1 phase arrest by upregulation of p21 protein [77]. Ajay kumar et al., reported that, BDCBMPE isolated from *Onosma bracteata* Wall shows significant anticancer activity by induction of early apoptosis by interfering G0/G1 phase of human osteosarcoma (MG-63) cells via Akt/NF- $\kappa$ B/p53 pathways [78]. Tseng et al., revealed that DHBA had potent anticancer effect by inducing cell cycle arrest and death in leukaemia cells (HL-60) via decreased RB and Bcl-2 expression and increased Bax expression [79]. Yang et al., found that the phytochemical EFDRLN shown substantial anticancer effect against cervical cancer cells (C33A and HeLa) in a dose-dependent manner via triggering apoptosis by modulating the levels of pro-apoptotic and anti-apoptotic proteins [80]. The obtained EFDRLN from *Aster tataricus* and *Vitex pendicularis* showed significant cervical cancer activity via increased level of caspase-3, -8 & -9 and also by reducing the level of Bcl-2, -xL and survivin respectively [81]. Based on the above reports the anticancer activity of chloroform fraction of DQR may be attributed to the presence of anticancer phytoconstituents and through above discussed anticancer mechanism.

## 5. Conclusion

The present study makes an effort to find the anticancer mechanism of DQR fractions. Among the fractions the chloroform shows promising anticancer activity by interfering with S-phase of cell cycle and by promoting apoptosis. Through literature we have identified 42 phytoconstituents of DQ which may be responsible for this anticancer activity. Further investigation may-shred more insights into the anticancer activity of this fraction.

### Source of funding

The All-India Council of Technical Education-National Doctoral Fellowship (AICTE-NDF), Government of India, New Delhi, funded this research through the project NDF (App 64879).

### Authors' Contributions

All authors contributed to data analysis, drafting and revising of the paper and agreed to be responsible for all the aspects of this work.

### Conflict of interest

The authors state that there is no conflict of interest.

### Acknowledgement

The authors would like to thank the All-India Council of Technical Education-National Doctoral Fellowship (AICTE-NDF), Government of India, New Delhi, for supporting the project through AICTE-NDF and the Department of Science and Technology- Fund for Improvement of Science and Technology Infrastructure in Universities and Higher Educational Institutions (DST-FIST), New Delhi- India for their infrastructure support to our department.

### Reference

- [1] M. Arnold, E. Morgan, H. Rungay, A. Mafra, D. Singh, M. Laversanne, J. Vignat, J.R. Gralow, F. Cardoso, S. Siesling, and I. Soerjomataram. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. *The Breast*. 66: 15. <https://doi.org/10.1016/j.breast.2022.08.010>.
- [2] N.A. Razak, N. Abu, W.Y. Ho, N.R. Zamberi, S.W. Tan, N.B. Alitheen, K. Long, and S.K. Yeap. (2019). Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. *Scientific Reports*. 9(1):1514. <https://doi.org/10.1038/s41598-018-37796-w>.
- [3] O.A. Bamodu, W.C. Huang, D.T. Tzeng, A. Wu, L.S. Wang, C.T. Yeh, and T.Y. Chao. (2015). Ovatioidiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity. *Cancer Letters*. 364(2): 125. <https://doi.org/10.1016/j.canlet.2015.05.006>.
- [4] C.A. Sánchez-Valdeolivar, P. Alvarez-Fitz, A.E. Zacapala-Gómez, M. Acevedo-Quiroz, L. Cayetano-Salazar, M. Olea-Flores, J.U. Castillo-Reyes, N. Navarro-Tito, C. Ortuño-Pineda, M.A. Leyva-Vázquez, and J. Ortíz-Ortíz. (2020). Phytochemical profile and antiproliferative effect of *Ficus crocata* extracts on triple-negative breast cancer cells. *BMC Complementary Medicine and Therapies*. 20: 1. <https://doi.org/10.1186/s12906-020-02993-6>.
- [5] J. Blasiak, E. Pawlowska, J. Chojnacki, J. Szczepanska, M. Fila, and C. Chojnacki. (2020). Vitamin D in triple-negative and BRCA1-deficient breast cancer—Implications for pathogenesis and therapy. *International Journal of Molecular Sciences*. 21(10): 3670. <https://doi.org/10.3390/ijms21103670>.
- [6] Z. Momenimovahed, and H. Salehiniya, (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer: Targets and Therapy*. 151. <https://doi.org/10.2147/BCTT.S176070>.
- [7] Y.S. Sun, Z. Zhao, Z.N. Yang, F. Xu, H.J. Lu, Z.Y. Zhu, W. Shi, J. Jiang, P.P. Yao, and H.P. Zhu. (2017). Risk factors and preventions of breast cancer. *International Journal of Biological Sciences*. 13(11): 1387. <https://doi.org/10.7150/ijbs.21635>.
- [8] D.J. Newman, G.M. Cragg, and K.M. Snader. (2000). The influence of natural products upon drug discovery. *Natural Product Reports*. 17(3):215. <https://doi.org/10.1039/A902202C>.
- [9] A.B. Da Rocha, R.M. Lopes, and G. Schwartsmann. (2001). Natural products in anticancer therapy. *Current Opinion in Pharmacology*. 1(4): 364. [https://doi.org/10.1016/S1471-4892\(01\)00063-7](https://doi.org/10.1016/S1471-4892(01)00063-7).
- [10] J. Khazir, B.A. Mir, L. Pilcher, and D.L. Riley. (2014). Role of plants in anticancer drug discovery. *Phytochemistry Letters*. 7: 173. <https://doi.org/10.1016/j.phytol.2013.11.010>.
- [11] G.M. Cragg, and D.J. Newman. (2005). Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology*. 100(1-2): 72. <https://doi.org/10.1016/j.jep.2005.05.011>.
- [12] V.V. Vaidya, S.H. Patil, D.D. Ghadge, and H.R. Shah. (2016). Physicochemical standardization and metal analysis of *Drynaria quercifolia* (L.) J. Sm. *World Journal of Pharmaceutical Research*. 5(6): 2140. <https://doi.org/10.20959/wjpr20166-6457>.
- [13] L. Janarathanan, V. arthikeyan, B.R. Balakrishnan, B. Jaykar, K.L. Senthilkumar, and G. Anadharaj. (2016). Pharmacognostical standardization and phytochemical profile of rhizomes of *Drynaria quercifolia* (Linn) J Smith. *European Journal of Biomedical Pharmaceutical Science*. 3(8): 278.
- [14] R.H.G. Ranil. (2008). Occurrence of *Drynaria sparsisora* (Desv.) T. Moore, in the lower Hantana area, Sri Lanka. *Journal of the National Science Foundation of Sri-Lanka*. 36(4): 331. <https://doi.org/10.4038/jnsfsr.v36i4.273>.
- [15] C. Sivaraj, Y. Aashinya, R. Sripriya, and P. Arumugam. (2018). Antioxidant Activities and Thin Layer Chromatographic Analysis of Aqueous Extract of Tubers of *Drynaria quercifolia* (L.) J. Sm. *Free Radicals and Antioxidants*. 8(1): 26. <https://doi.org/10.5530/fra.2018.1.5>.
- [16] B. Janaranjani, G. Prasanna, and M. Chitra. (2014). Anti-inflammatory and Antipyretic Activities of *Drynaria quercifolia* Rhizome in Rats. *International Journal of Pharmaceutical Science Review and Research*. 13: 57.
- [17] P. Samyudurai, V. Thangapandian, and Aravinthan. (2012). Wild habits of Kolli Hills being staple food of inhabitant tribes of Eastern Ghats, Tamil Nadu, India. *Indian Journal of Natural Products and Resources*. 2012: 432.

- [18] G. Perumal. (2010). Ethnomedicinal use of pteridophyte from Kolli hills, Namakkal district, Tamil Nadu, India. *Ethnobotanical Leaflets*. 2: 5.
- [19] D.V. Pawar, D.K.T. Chandrashekar, D.R. Mishra, D.V. Tripathi, D.K. Tripathi. (2017). *Drynaria Quercifolia* Plant Extract as A Bone Regenerative Material in The Treatment of Periodontal Intrabony Defects: Clinical and Radiographic Assessment. *IOSR Journal of Dental and Medical Sciences*. 16 (03): 93. <https://doi.org/10.9790/0853-1603069399>.
- [20] G. Prasanna, R. Devi, G. and Ishwarya. (2019). In vitro evaluation of antidiabetic and cytotoxicity potentials of the rhizome extract of *Drynaria quercifolia* (L.) J. *Asian Journal of Pharmaceutical and Clinical Research*. 12(11): 72. <http://dx.doi.org/10.22159/ajpcr.2019.v12i11.35078>
- [21] N. Ramesh, M.B. Viswanathan, A. Saraswathy, K. Balakrishna, P. Brindha, and P. Lakshmanaperumalsamy. (2001). Phytochemical and antimicrobial studies on *Drynaria quercifolia*. *Fitoterapia*. 72(8): 934. [https://doi.org/10.1016/S0367-326X\(01\)00342-2](https://doi.org/10.1016/S0367-326X(01)00342-2).
- [22] G. Prasanna and M. Chitra. (2014). Phytochemical screening and GC-MS analysis of *Drynaria quercifolia* rhizome. *American Journal of Advanced Drug Delivery*. 3: 72.
- [23] A. Khan, E. Haque, M. Rahman, A. Mosaddik, M. Rahman, and N. Sultana. (2007). Isolation of antibacterial constituent from rhizome of *Drynaria quercifolia* and its sub-acute toxicological studies. *DARU Journal of Pharmaceutical Sciences*. 15(4): 205.
- [24] M.K. Nithin, G. Veeramani, and S. Sivakrishnan. (2020). Phytochemical screening and GC-MS analysis of rhizome of *Drynaria quercifolia*. *Research Journal of Pharmacy and Technology*. 13(5): 2266. <https://doi.org/10.5958/0974-360X.2020.00408.4>.
- [25] D. Choi, W. Kang, and T. Park. (2020). Anti-allergic and anti-inflammatory effects of undecane on mast cells and keratinocytes. *Molecules*. 25(7): 1554. <https://doi.org/10.3390/molecules25071554>.
- [26] M.F. Moustafa, S.A. Alamri, T.H. Taha, and S.A. Alrumman. (2013). In vitro antifungal activity of *Argemone ochroleuca* sweet latex against some pathogenic fungi. *African Journal of Biotechnology*. 12(10): 1132. <https://doi.org/10.5897/AJB12.2649>
- [27] O.O. Mebude, and B. Adeniyi. (2017). GC-MS analysis of phyto components from the stem bark of *Cola nitida* Schott & Endl. *Journal of Plant Sciences*. 5(4): 99. <https://doi.org/10.11648/j.jps.20170504.11>.
- [28] G. Gnanashree, and P.M. Sirajudeen. (2018). Determination of bioactive compounds in ethanolic extract of *Caralluma indica* using GC-MS technique. *Journal of Pharmacognosy and Phytochemistry*. 7(6): 1675.
- [29] N. Premjanu, and C. Jaynthy. (2014). Antimicrobial activity of diethyl phthalate: An insilico approach. *Asian Journal of Pharmaceutical and Clinical Research*. 7(4): 141.
- [30] O. Isbilen, N. Rizaner, and E. Volkan. (2018). Anti-proliferative and cytotoxic activities of *Allium autumnale* PH Davis (Amaryllidaceae) on human breast cancer cell lines MCF-7 and MDA-MB-231. *BMC Complementary and Alternative Medicine*. 18: 1. <https://doi.org/10.1186/s12906-018-2105-0>.
- [31] S.K. Sudirga, and I.K. Ginantara. (2017). Identification of bioactive compounds of *Ficus septica* leaf extract has potential as botanical pesticides to control anthracnose disease on chili pepper. *Journal of Biological Chemistry*. 34: 150.
- [32] A. Kumar, S. Kaur, S. Dhiman, P.P. Singh, S. Thakur, U. Sharma, S. Kumar, and S. Kaur. (2021). 1, 2-benzenedicarboxylic acid, bis (2-methyl propyl) ester isolated from *Onosma bracteata* Wall. inhibits MG-63 cells proliferation via Akt-p53-cyclin pathway. In Review. 2021, <https://doi.org/10.21203/rs.3.rs-182390/v1>.
- [33] D.S. Devi., H.A. Pranathi. S3, Ravindar Gundeti2, Chandra shekar. S4. GC-MS analysis of phytochemical constituents and screening for antibacterial activity of the methanol leaf extract of *Amaranthus viridis* linn. Against human pathogenic bacteria. *Indo American Journal of Pharmaceutical research*. 7(2): 7773. <https://doi.org/10.5281/zenodo.2383673>.
- [34] G. Belakhdar, A. Benjouad, and E.H. Abdennebi. (2015). Determination of some bioactive chemical constituents from *Thesium humile* Vahl. *Journal of Materials and Environmental Science*. 6(10): 2778.
- [35] S. Arora, and G. Kumar. (2017). Gas Chromatography-Mass Spectrometry (GC-MS) determination of bioactive constituents from the methanolic and Ethyl acetate extract of *Cenchrus setigerus* Vahl (Poaceae). *The Pharma Innovation Journal*. 6(11): 635.
- [36] K. Krishnamoorthy, and P. Subramaniam. (2014). Phytochemical profiling of leaf, stem, and tuber parts of *Solena amplexicaulis* (Lam.) Gandhi using GC-MS. *International Scholarly Research Notices*. 1. <https://doi.org/10.1155/2014/567409>.
- [37] M.N. Abubakar, and R.R. Majinda. (2016). GC-MS analysis and preliminary antimicrobial activity of *Albizia adianthifolia* (Schumach) and *Pterocarpus angolensis* (DC). *Medicines*. 3(1): 3. <https://doi.org/10.3390/medicines3010003>.
- [38] G.G. Beulah, P.T. Soris, and V.R. Mohan. (2018). GC-MS determination of bioactive compounds of *Dendrophthoe falcata* (LF) Ettingsh: An epiphytic plant. *International Journal of Health Sciences and Research*. 8: 261.
- [39] D. Kumar, M. Karthik, and R. Rajakumar. (2018). GC-MS analysis of bioactive compounds from ethanolic leaves extract of *Eichhornia crassipes* (Mart) Solms. and their pharmacological activities. *Journal of Pharmaceutical Innovation*. 7(8): 459.
- [40] A. Ali, A. Javaid, A. Shoaib. (2017). GC-MS analysis and antifungal activity of methanolic root extract of *Chenopodium Album* against *Sclerotium*

- Rolfsii. *Planta Daninha*. 35(0): 1. <https://doi.org/10.1590/S0100-83582017350100046>
- [41] A.S. Adegoke, O.V. Jerry, and O.G. Ademola. (2019). GC-MS analysis of phytochemical constituents in methanol extract of wood bark from *Durio zibethinus* Murr. *International Journal of Medicinal Plants and Natural Products*. 5(3): 1. <https://doi.org/10.20431/2454-7999.0503001>.
- [42] A.Y. Shettima, Y. Karumi, O.A. Sodipo, H. Usman, and M.A. Tijjani. (2013). Gas Chromatography-Mass Spectrometry (GC-MS) analysis of bioactive components of Ethylacetate root extract of *Guiera senegalensis* JF Gmel. *Journal of Applied Pharmaceutical Science*. 3(3): 14. <https://doi.org/10.7324/JAPS.2013.30328>.
- [43] A.K. Khan, R. Rashid, N. Fatima, S. Mahmood, S. Mir, S. Khan, N. Jabeen, and G. Murtaza. (2015). Pharmacological activities of protocatechuic acid. *Acta Poloniae Pharmaceutica*. 72(4): 643.
- [44] Y. Zhao, and S. Liu. (2021). Bioactivity of naringin and related mechanisms. *Die Pharmazie. An International Journal of Pharmaceutical Sciences*. 76(8): 359. <https://doi.org/10.1691/ph.2021.1504>.
- [45] B. Salehi, P.V.T. Fokou, M. Sharifi-Rad, P. Zucca, R. Pezzani, N. Martins, and J. Sharifi-Rad. (2019). The therapeutic potential of naringenin: a review of clinical trials. *Pharmaceuticals*. 12(1): 11. <https://doi.org/10.3390/ph12010011>.
- [46] T. Jabri, M. Imran, A. Aziz, K. Rao, M. Kawish, M. Irfan, M.I. Malik, S.U. Simjee, M. Arfan, and M.R. Shah. (2019). Design and synthesis of mixed micellar system for enhanced anticancer efficacy of Paclitaxel through its co-delivery with Naringin. *Drug Development and Industrial Pharmacy*. 45(5): 703. <https://doi.org/10.1080/03639045.2018.1550091>.
- [47] S. Rajamani, A. Radhakrishnan, T. Sengodan, and S. Thangavelu. (2018). Augmented anticancer activity of naringenin-loaded TPGS polymeric nanosuspension for drug resistive MCF-7 human breast cancer cells. *Drug Development and Industrial Pharmacy*. 44(11): 1752. <https://doi.org/10.1080/03639045.2018.1496445>.
- [48] R.B. Devi, T.N. Barkath, P. Vijayaraghavan, and T.S. Rejiniemon. (2018). Gc-MS Analysis of Phytochemical from *Psidium guajava* Linn Leaf Extract and Their Invitro Antimicrobial Activities. *International Journal of Pharmacy and Biological Sciences*. 8: 583.
- [49] P.S. Mary. (2018). Gas chromatography and mass spectrometry of the ethanolic extract of nest material of mud dauber wasp, *sceliphron caementarium*. *Asian Journal of Pharmaceutical and Clinical Research*. 234. <https://doi.org/10.22159/ajpcr.2018.v11i7.23611>.
- [50] J. Saikarthik, S. Ilango, J. Vijayakumar, and R. Vijayaraghavan. (2017). Phytochemical analysis of methanolic extract of seeds of *Mucuna pruriens* by gas chromatography mass spectrometry. *International Journal of Pharmaceutical Sciences and Research*. 8(7): 2916. [http://dx.doi.org/10.13040/IJPSR.0975-8232.8\(7\).2916-21](http://dx.doi.org/10.13040/IJPSR.0975-8232.8(7).2916-21).
- [51] P. Antonisamy, V. Duraipandiyan, and S. Ignacimuthu. (2011). Anti-inflammatory, analgesic and antipyretic effects of friedelin isolated from *Azima tetracantha* Lam. in mouse and rat models. *Journal of Pharmacy and Pharmacology*. 63(8): 1070. <https://doi.org/10.1111/j.2042-7158.2011.01300.x>.
- [52] C. Sunil, S.S. Irudayaraj, V. Duraipandiyan, S.T. Alrashood, S.A. Alharbi, and S. Ignacimuthu. (2021). Friedelin exhibits antidiabetic effect in diabetic rats via modulation of glucose metabolism in liver and muscle. *Journal of Ethnopharmacology*. 268: 113659. <https://doi.org/10.1016/j.jep.2020.113659>.
- [53] K. Yessoufou, H.O. Elansary, E.A. Mahmoud, and K. Skalicka-Woźniak. (2015). Antifungal, antibacterial and anticancer activities of *Ficus drupacea* L. stem bark extract and biologically active isolated compounds. *Industrial Crops and Products*. 74: 752. <https://doi.org/10.1016/j.indcrop.2015.06.011>.
- [54] B. Emsen, T. Engin, and H. Turkez. (2018). In vitro investigation of the anticancer activity of friedelin in glioblastoma multiforme. *Afyon Kocatepe Üniversitesi Fen ve Mühendislik Bilimleri Dergisi*. 18(3): 763. <https://doi.org/10.5578/fmbd.67733>.
- [55] P.C. Perumal, S. Sowmya, D. Velmurugan, T. Sivaraman, and V.K. Gopalakrishnan. (2016). Assessment of dual inhibitory activity of epifriedelanol isolated from *Cayratia trifolia* against ovarian cancer. *Bangladesh Journal of Pharmacology*. 11(2): 545. <https://doi.org/10.3329/bjp.v11i2.24933>.
- [56] T.D. Viet, T.D. Xuan, L.H. and Anh. (2021).  $\alpha$ -Amyrin and  $\beta$ -Amyrin isolated from *celastrus hindsii* leaves and their antioxidant, anti-xanthine oxidase, and anti-tyrosinase potentials. *Molecules*. 26(23): 7248. <https://doi.org/10.3390/molecules26237248>.
- [57] R. Kumar, B. Kumar, A. Kumar, A. Kumar, and M. Singh. (2022). GC-MS analysis of Phytocomponents in the Methanol Extract of *Premna latifolia* Roxb. *Pharmacognosy Research*. 14(1): 19. <https://doi.org/10.5530/pres.14.1.4>.
- [58] F.A. Santos, J.T. Frota, B.R. Arruda, T.S. de Melo, A.A.D.C.A. da Silva, G.A.D.C. Brito, M.H. Chaves, and V.S. Rao. (2012). Antihyperglycemic and hypolipidemic effects of  $\alpha$ ,  $\beta$ -amyrin, a triterpenoid mixture from *Protium heptaphyllum* in mice. *Lipids in Health and Disease*. 11(1): 1. <https://doi.org/10.1186/1476-511X-11-98>.
- [59] J.W. Chai, U.R. Kuppusamy, and M.S. Kanthimathi. (2008). Beta-sitosterol induces apoptosis in MCF-7 cells. *Malaysian Journal of Biochemistry and Molecular Biology*. 16(2): 28.
- [60] G.K. Jayaprakasha, K.K. Mandadi, S.M. Poulouse, Y. Jadegoud, G.N. Gowda, and B.S. Patil. (2007). Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from *Poncirus trifoliata* (L.) Raf. *Bioorganic &*



- Medicinal Chemistry. 15(14): 4923. <https://doi.org/10.1016/j.bmc.2007.04.044>.
- [61] R. Utami, N. Khalid, M.A. Sukari, M. Rahmani, and A.B. Abdul. (2013). Phenolic contents, antioxidant and cytotoxic activities of *Elaeocarpus floribundus* Blume. *Pakistan Journal of Pharmaceutical Sciences*. 26(2): 245.
- [62] M. Mariquit, G.G. Oyong, V.D. Ebajo Jr, V.A.S. Ng, C.C. Shen, and C.Y. Ragasa. (2015). Cytotoxic Triterpenes and Sterols from *Pipturus arborescens* (Link) CB Rob. *Journal of Applied Pharmaceutical Science*. 5(11): 023. <https://doi.org/10.7324/JAPS.2015.501104>.
- [63] C.A. Ukwubile, E.O. Ikpefan, T.S. Malgwi, A.B. Bababe, J.A. Odugu, A.N. Angyu, O. Otal, M.S. Bingari, and H.I. Nettey. (2020). Cytotoxic effects of new bioactive compounds isolated from a Nigerian anticancer plant *Melastomastrum capitatum* Fern. leaf extract. *Scientific African*. 8: 00421 <https://doi.org/10.1016/j.sciaf.2020.e00421>.
- [64] L. Novotny, M.E. Abdel-Hamid, and L. Hunakova. (2017). Anticancer potential of  $\beta$ -sitosterol. *International Journal of Clinical Pharmacology and Pharmacotherapy*. 2. <https://doi.org/10.15344/2456-3501/2017/129>.
- [65] X. Bao, Y. Zhang, H. Zhang, and L. Xia. (2022). Molecular Mechanism of  $\beta$ -Sitosterol and its Derivatives in Tumor Progression. *Frontiers in Oncology*. 12: 926975 <https://doi.org/10.3389/fonc.2022.926975>
- [66] H. Li, B. Yang, J. Huang, T. Xiang, X. Yin, J. Wan, F. Luo, L. Zhang, H. Li, and G. Ren. (2013). Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting  $\beta$ -catenin signaling pathway. *Toxicology Letters*. 220(3): 219. <https://doi.org/10.1016/j.toxlet.2013.05.006>.
- [67] A. Prabhu, M. Krishnamoorthy, D.J. Prasad, P. Naik. (2011). Anticancer activity of friedelin isolated from ethanolic leaf extract of *Cassia tora* on HeLa and HSC-1 cell lines. *Indian Journal of Applied Research*. 3(10): 1. <https://doi.org/10.15373/2249555X/OCT2013/121>
- [68] F.R. Yu, X.Z. Lian, H.Y. Guo, P.M. McGuire, R.D. Li, R. Wang, and F.H. Yu. (2005). Isolation and characterization of methyl esters and derivatives from *Euphorbia kansui* (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells. *Journal of Pharmacy and Pharmaceutical Sciences*. 8(3): 528.
- [69] F. Maiyoa, R. Moodley, and M. Singh. (2016). Phytochemistry, cytotoxicity and apoptosis studies of  $\beta$ -sitosterol-3- $\beta$ -D-glucoside and  $\beta$ -amyrin from *Prunus Africana*. *African Journal of Traditional, Complementary and Alternative Medicines*. 13(4): 105. <https://doi.org/10.21010/ajtcam.v13i4.15>.
- [70] T.K. Vo, Q.T.H. Ta, Q.T. Chu, T.T. Nguyen, and V.G. Vo. (2021). Anti-hepatocellular-cancer activity exerted by  $\beta$ -sitosterol and  $\beta$ -sitosterol- $\beta$ -D-glucoside from *Indigofera zollingeriana* miq. *Molecules*. 25(13): 3021. <https://doi.org/10.3390/molecules25133021>.
- [71] Y. Zhao, S.K. Chang, G. Qu, T. Li, and H. Cui. (2009).  $\beta$ -Sitosterol inhibits cell growth and induces apoptosis in SGC-7901 human stomach cancer cells. *Journal of Agricultural and Food Chemistry*. 57(12): 5211. <https://doi.org/10.1021/jf803878n>.
- [72] S.S. Vundru, R.K. Kale, and R.P. Singh. (2013).  $\beta$ -sitosterol induces G1 arrest and causes depolarization of mitochondrial membrane potential in breast carcinoma MDA-MB-231 cells. *BMC Complementary and Alternative Medicine*. 13(1): 1. <https://doi.org/10.1186/1472-6882-13-280>.
- [73] B. Ramu, K. Kaushal, P. Chandrul, S. Pandiyani. (2021). Using 24 Factorial Designs optimization of Repaglinide Gastroretentive Drug Delivery System. *Research Journal of Pharmacy and Technology*. 14(2): 725-729.
- [74] P. Subash-Babu, D.K. Li, A.A. and Alshatwi. (2017). In vitro cytotoxic potential of friedelin in human MCF-7 breast cancer cell: Regulate early expression of Cdkn2a and pRb1, neutralize mdm2-p53 amalgamation and functional stabilization of p53. *Experimental and Toxicologic Pathology*. 69(8): 630. <https://doi.org/10.1016/j.etp.2017.05.011>.
- [75] S. Wen, D. Gu, and H. Zeng. (2018). Antitumor effects of beta-amyrin in Hep-G2 liver carcinoma cells are mediated via apoptosis induction, cell cycle disruption and activation of JNK and P38 signalling pathways. *Journal of Balkan Union of Oncology*. 23: 965.
- [76] R. Banjerpongchai, B. Wudtiwai, and P. Khawon. (2016). Induction of human hepatocellular carcinoma HepG2 cell apoptosis by naringin. *Asian Pacific Journal of Cancer Prevention*. 17 (7): 3289.
- [77] R. Chen, Q.L. Qi, M.T. Wang, and Q.Y. Li. (2016). Therapeutic potential of naringin: an overview. *Pharmaceutical Biology*. 54(12): 3203 <https://doi.org/10.1080/13880209.2016.1216131>.
- [78] A. Kumar, S. Kaur, S. Dhiman, P.P. Singh, G. Bhatia, S. Thakur, H.S. Tuli, U. Sharma, S. Kumar, A.G. Almutary, and A.M. Alnuqaydan. (2022). Targeting Akt/NF- $\kappa$ B/p53 Pathway and Apoptosis Inducing Potential of 1, 2-Benzenedicarboxylic Acid, Bis (2-Methyl Propyl) Ester Isolated from *Onosma bracteata* Wall. against Human Osteosarcoma (MG-63) Cells. *Molecules*. 27 (11): 3478 <https://doi.org/10.3390/molecules27113478>
- [79] T.H. Tseng, T.W. Kao, C.Y. Chu, F.P. Chou, W.L. Lin, and C.J. Wang. (2000). Induction of apoptosis by hibiscus protocatechuic acid in human leukemia cells via reduction of retinoblastoma (RB) phosphorylation and Bcl-2 expression. *Biochemical Pharmacology*. 60(3): 307 [https://doi.org/10.1016/S0006-2952\(00\)00322-1](https://doi.org/10.1016/S0006-2952(00)00322-1).
- [80] J. Yang, J. Fa, and B. Li. (2017). Apoptosis induction of epifriedelinol on human cervical cancer cell line. *African Journal of Traditional, Complementary and Alternative Medicines*. 14(4): 80. <https://doi.org/10.21010/ajtcam.v14i4.10>.
- [81] [81] D. Mukherjee, D. Lahiri, and M. Nag. (2022). Therapeutic Effects of Natural Products Isolated from Different Microorganisms in Treating Cervical Cancer: A Review. *Cancer*



Insight. 1(2):31

<https://doi.org/10.58567/ci01020003>.